Peptide Schedule
Bonothyrk6 residuesAEDLRGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Bonothyrk Dosage Calculator
Bonothyrk is a bovine-derived peptide bioregulator containing a standardized extract of polypeptides from the parathyroid glands of young animals.
10mcg · Daily
Summary: Add 0mL BAC water to your 20mg vial. Draw to < 0.1 units on a U-100 syringe for a 10mcg dose. This vial will last 0 doses.
Cycle Planner
Bonothyrk Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~2-6 hours (estimated, polypeptide complex)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Bonothyrk Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mg | Daily |
| Moderate | 10mg | 2x Daily |
| Aggressive | 20mg | 2x Daily |
Note: Bonothyrk (A-21) is a natural peptide bioregulator derived from the parathyroid glands of young cattle. It belongs to the Khavinson class of cytomedins — tissue-specific polypeptide fractions developed at the St. Petersburg Institute of Bioregulation and Gerontology. Capsules typically contain 10 mg of the parathyroid peptide complex. Because it's a complex mixture of short-chain peptides rather than a single defined molecule, precise pharmacokinetic data for individual components isn't available. Standard protocols call for 1-2 capsules taken 1-2 times daily with meals over a 30-day course, repeated 2-3 times per year.
About Bonothyrk
Bonothyrk is a bovine-derived peptide bioregulator containing a standardized extract of polypeptides from the parathyroid glands of young animals. Designated as Peptide Complex A-21, it was developed by Professor Vladimir Khavinson's research group at the St. Petersburg Institute of Bioregulation and Gerontology as part of a broader program that produced over 20 tissue-specific bioregulators over four decades of research. The preparation targets parathyroid gland cells with the goal of normalizing intracellular metabolism and restoring the gland's ability to properly regulate calcium homeostasis. Khavinson's bioregulatory theory proposes that short peptides (2-7 amino acid residues) can penetrate cell nuclei, interact with specific promoter regions of DNA, and modulate gene expression through epigenetic mechanisms including DNA methylation status changes. When applied to parathyroid tissue, this is thought to restore age-related declines in parathyroid hormone (PTH) regulation, helping maintain normal blood calcium and phosphorus levels. One clinical observation tracked 33 perimenopausal women aged 47-56 with high osteoporosis risk who received Bonothyrk (two capsules twice daily for 30 days). The treated group showed measurable improvements in bone mineral density parameters compared to controls. It's worth noting that published evidence specific to Bonothyrk remains limited and is largely confined to Russian-language medical literature. No peer-reviewed PubMed-indexed studies focus exclusively on this preparation. The broader class of Khavinson bioregulators has been studied more extensively, but most Western researchers haven't independently replicated the parathyroid-specific findings.